Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
How is Abasaglar® (insulin glargine) therapy initiated and titrated?
The recommended initial dose of Abasaglar is approximately one-third of the total daily insulin requirement for type 1 diabetes and up to 10 units once daily for type 2 diabetes. A titration schedule of 1 unit per day was used for type 2 diabetes.
Initiation of Abasaglar Therapy
The recommended initial dose of Abasaglar (insulin glargine) 100 units/mL differs between patients with type 1 or type 2 diabetes (Table 1).1
If treating patients with...
Then the recommended initial dose of Abasaglar is...
type 1 diabetes
approximately 1/3 of the total daily insulin requirement.
type 2 diabetes
0.2 units/kg or up to 10 units once daily.
Abbreviations: Abasaglar = Abasaglar® (insulin glargine) 100 units/mL.
Patients with type 1 diabetes should use short- or rapid-acting premeal insulin for their remaining daily insulin requirements.1
Patients with type 2 diabetes may need to adjust the dose of their concomitant antihyperglycemic medications.1
Titration of Abasaglar in ELEMENT 2 Study
ELEMENT 2 (a prospEctive, randomized, doubLE-blind coMparison of a long-acting basal insulin analog LY2963016 to Lantus® in adult patiENTs with type 2 diabetes mellitus) was a phase 3 study that compared the efficacy and safety of Abasaglar vs Lantus® (insulin glargine) 100 units/mL in patients with type 2 diabetes.2
The initial dose of Abasaglar and Lantus for insulin-naïve patients was 10 units once daily.2
Patients previously prescribed Lantus initiated Abasaglar or Lantus at the prestudy Lantus dose.2
The insulin dose could be
- increased if deemed necessary by the investigator, or
- decreased if patients experienced hypoglycemia.4
Approximately 50% of patients in each treatment group
- injected their basal insulin in the daytime, or
- injected their dose in the evening or at bedtime.4
Titration of Insulin Glargine in INSIGHT Study
The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment) study was conducted in 405 insulin-naïve patients with type 2 diabetes.3
The initial dose of insulin glargine was 10 units once daily.3
A simple protocol of 1 unit per day was used for introduction of insulin glargine and self-titration of the glargine.3
Insulin glargine was injected at the same time each evening. 3
This insulin glargine protocol was 1.7 times more likely to safely achieve near-physiological control, defined as 2 consecutive HbA1c levels less than 6.5%, than conventional therapy with oral antihyperglycemic medications.3
1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734-741. https://doi.org/10.1111/dom.12482
3Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med. 2006;23(7):736-742. http://dx.doi.org/10.1111/j.1464-5491.2006.01881.x
4Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: July 27, 2021